228 related articles for article (PubMed ID: 15951469)
1. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
Ng CM; Bruno R; Combs D; Davies B
J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
[TBL] [Abstract][Full Text] [Related]
2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
3. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
[TBL] [Abstract][Full Text] [Related]
6. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
Yukawa E; Mori S; Ueda K; Nakada Y
J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
[TBL] [Abstract][Full Text] [Related]
10. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Vakily M; Amer F; Kukulka MJ; Andhivarothai N
J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
13. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
Mould DR; Davis CB; Minthorn EA; Kwok DC; Elliott MJ; Luggen ME; Totoritis MC
Clin Pharmacol Ther; 1999 Sep; 66(3):246-57. PubMed ID: 10511060
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
17. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
18. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
Renato GM
Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
[TBL] [Abstract][Full Text] [Related]
19. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
[TBL] [Abstract][Full Text] [Related]
20. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
